Evaluation of Geriatric Assessment Tools in Elderly Patients with MM

Conference Correspondent - TON - ASH 2015 - Multiple Myeloma

Geriatric assessment (GA) tools have been developed to help determine the capabilities and needs of elderly patients with multiple myeloma (MM). There are concerns that scoring tools developed in clinical trials may have limited applicability in the real-world treatment setting. In this study, researchers prospectively evaluated patients aged >65 years with symptomatic MM to evaluate several different GA tools (including the International Myeloma Working Group [IMWG] “frailty score” and the G8-geriatric assessment screening [GAS] tool) and comorbidity indices, along with standard disease-related prognostic factors.

At baseline, the median age of patients with a GA was 76 years (range, 66-92); 55% were males; 26% had ISS-1, 24% ISS-2, and 50% ISS-3. A total of 47% of patients received immunomodulator-based treatment, and 53% were treated with proteasome inhibitors. Median follow-up was 20 months. Two-year overall survival (OS) was 71%.

In univariate analyses of GA tools, several variables were found to have prognostic significance, including:

  • Number of falls in the past 6 months (0 vs ≥1; P = .002)
  • Lower extremity function (score <9 vs ≥9; P = .014)
  • Mini-nutritional assessment (score <11 vs ≥11; P = .014)
  • G8-GAS (score <12 vs ≥12; P <.001)
  • Karnofsky Index of Performance Status <50% (P <.001)
  • Eastern Cooperative Oncology Group Performance Status >2 (P = .04)
  • Mini-Mental State Examination (score ≥6 vs <6; P = .024)

In a multivariate analysis, which included ISS and age, number of falls in the past 6 months (0 vs ≥1; hazard ratio [HR], 4.7; P = .007) and score <12 in the G8-GAS tool (HR, 4.7; P = .004) were independent factors for survival.

Researchers concluded that in elderly myeloma patients, G8-GAS provides prognostic information related to the risk of early death and OS, independently from disease characteristics and the treatment type. Although the IMWG “frailty score” may be useful for patients fit to participate in clinical trials, this metric appeared to have limited prognostic utility in a real-world patient setting.

Related Items
Racial Disparities in Incidence and Survival for Patients with Multiple Myeloma in the United States
Conference Correspondent published on December 8, 2015 in TON - ASH 2015 - Multiple Myeloma
The Significant Contribution of Pain in Determining the Health Status of Patients with Multiple Myeloma
Conference Correspondent published on December 8, 2015 in TON - ASH 2015 - Multiple Myeloma
Incidence of Falls Is Common in Older Adults with Newly Diagnosed MM
Conference Correspondent published on December 8, 2015 in TON - ASH 2015 - Multiple Myeloma
Improving the Management of Patients on Oral Regimens
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on December 8, 2015 in TON - ASH 2015 - Multiple Myeloma
Utilizing Patient Support Services
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on December 7, 2015 in TON - ASH 2015 - Multiple Myeloma
Elotuzumab plus Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 2 Study (CA204-009T)
Conference Correspondent published on December 7, 2015 in TON - ASH 2015 - Multiple Myeloma
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)
Conference Correspondent published on December 7, 2015 in TON - ASH 2015 - Multiple Myeloma
Natural History of Relapsed MM After Initial Relapse
Conference Correspondent published on December 7, 2015 in TON - ASH 2015 - Multiple Myeloma
Ixazomib plus Lenalidomide/Dexamethasone Significantly Prolongs Progression-Free Survival for Patients with RRMM in the Phase 3 Tourmaline-MM1 Study
Conference Correspondent published on December 7, 2015 in TON - ASH 2015 - Multiple Myeloma
The Relevance of Minimal Residual Disease Monitoring in Elderly Multiple Myeloma Patients
Conference Correspondent published on December 7, 2015 in TON - ASH 2015 - Multiple Myeloma
Last modified: December 8, 2015